Journal: mAbs
Article Title: Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer.
doi: 10.1080/19420862.2024.2387240
Figure Lengend Snippet: Figure 1. Discovery and characterization of the PSCA antibody fab G7.(a) fab G7 binding to recombinant PSCA-Fc protein measured by ELISA. Bovine serum albumin (BSA) was used as a negative control. Experiments were performed in duplicate and the error bars denote ± SD, n = 2. (b) Kinetics of fab G7 binding to PSCA-Fc, as measured by Blitz. (c) Fab G7 binding to PSCA positive (PC-3-PSCA, Du-145-PSCA and HT1376 cells) and PSCA negative cells (PC-3, Du-145 and CHO-K1 cells) as tested by flow cytometry. An irrelevant fab (anti-SARS-CoV-2 fab ab1) was used as the isotype control. Fab G7 at the concentration of 500 nM was incubated with cells. (d-g) competition of fab G7 and fab F12 binding to HT1376 cell surface-associated PSCA by the recombinant PSCA-Fc protein (d and f) and by the murine PSCA antibody 7F5 (e and g). 500 nM of fab G7 or 200 nM of F12 was incubated with cells in the presence of gradient concentration of competitors. The bound fab G7 or F12 was detected by the pe-conjugated anti-flag tag antibody.
Article Snippet: The prostate cancer cell lines PC-3 and Du-145 and the bladder cancer cell-line HT1376 were purchased from the American Type Culture Collection (ATCC).
Techniques: Binding Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Negative Control, Flow Cytometry, Control, Concentration Assay, Incubation, FLAG-tag